A study attempting to characterize the true preventability of venous thromboembolism determined that financial penalties based on the total number of patients who suffer blood clots in the lung or leg may be unfairly imposed.
A study attempting to characterize the true preventability of venous thromboembolism (VTE) determined that financial penalties based on the total number of patients who suffer blood clots in the lung or leg may be unfairly imposed.
Researchers with Johns Hopkins University School of Medicine reviewed 128 medical case histories and came to the conclusion that the current pay-for-performance system is a problem. Elliott R. Haut, MD, PhD, an associate professor of surgery at the Johns Hopkins University School of Medicine, explained that even when hospitals do everything they can to prevent VTE, they can still be penalized for patients who develop blood clots.
Nearly half of VTE events identified by the Maryland state program were not truly preventable, he said.
“We know we’re not going to get the VTE rate to zero, but my goal is to have every single one of these events—when they happen—occur when the patient receives best-practice, defect-free care,” Dr Haut said in a statement.
If the findings hold true across the state of Maryland and the rest of the country, hospitals may be penalized millions of dollars through inappropriate fines.
In a research letter published in JAMA Surgery, Dr Haut and his colleagues noted that even with the use of blood thinners and other best practices, some patients will still develop clots. Meanwhile, government regulatory agencies and health insurers are increasingly tracking the number of patients who develop blood clots and imposing financial penalties.
The researchers argue that instead of looking solely at total numbers of patients who develop clots, a better measure would be to track whether patients at risk for clots were appropriately prescribed and given clot-preventing medications.
“To reduce preventable harm, policymakers need to re-evaluate how they penalize hospitals and improve the measures they use to assess VTE prevention performance,” Dr Haut said. “In addition, clinicians need to ensure that patients receive all prescribed preventive therapies.”
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Study Highlights Disparities in Access to In-Network Mental Health Care vs Medical Care
April 17th 2024While health plans often employ reimbursement rates as a tool to incentivize provider participation within their networks, study results showed reimbursement rates for office visits with medical/surgical clinicians were on average 22% higher than behavioral health clinicians.
Read More